Clinical Report: Can Treprostinil Change IPF Care?
Overview
The phase 3 TETON-1 trial evaluated inhaled treprostinil in 598 patients with idiopathic pulmonary fibrosis (IPF), finding a smaller decline in forced vital capacity (FVC) and fewer clinical worsening events compared to placebo over 52 weeks.
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by a decline in lung function and poor prognosis. Current treatment options primarily include antifibrotic therapies like nintedanib and pirfenidone.
Data Highlights
| Parameter | Treprostinil | Placebo |
|---|---|---|
| Median Change in FVC at Week 52 | -43 mL | -196 mL |
| Clinical Worsening Events | 32% | 45% |
| Adverse Events Leading to Discontinuation | 21% | 15% |
Key Findings
- Treatment with inhaled treprostinil resulted in a smaller decline in FVC compared to placebo (−43 mL vs. −196 mL).
- Clinical worsening occurred in 32% of patients receiving treprostinil versus 45% in the placebo group.
- A relative decline of at least 10% in predicted FVC was the most common clinical worsening event.
- Cough was reported in 55% of patients receiving treprostinil compared to 33% receiving placebo.
- Serious adverse events occurred in 18% of treprostinil patients and 24% of placebo patients.
- Overall treatment discontinuation rates were 41% for treprostinil and 33% for placebo.
Clinical Implications
Clinicians should consider the findings from the TETON-1 trial when discussing treatment options with patients.
Conclusion
Inhaled treprostinil shows a reduction in FVC decline and clinical worsening in IPF patients.
Related Resources & Content
- Nathan SD, et al., The New England Journal of Medicine, 2026 -- Can Treprostinil Change IPF Care?
- MDSpire News — New Inhaled Treprostinil Option Approved
- reuters — Treprostinil Approval Stalled by FDA
- Drugs - Real World Outcomes — Exploring Medication Compliance and Healthcare Expenditures in Patients with Pulmonary Arterial Hypertension Receiving Oral Prostacyclins: A Retrospective Analysis
- Clinical Rheumatology — Management of Digital Ulcers in Systemic Sclerosis: Recent Advances and Future Directions
- New Inhaled Treprostinil Option Approved
- Treprostinil Approval Stalled by FDA
- Exploring Medication Compliance and Healthcare Expenditures in Patients with Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
- oup.silverchair-cdn.com
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease | New England Journal of Medicine
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
